Starling Oncology stock
STLNNASDAQStarling Oncology, Inc., HealthcareISIN US68236X1000
26Score 26 out of 100, Weak
Price and trend
44 / 100
Price history
−35% since 2026The chart shows daily closing prices since 7 Jul 2026, adjusted for stock splits and excluding dividends. Click into the chart to set a price alert at that price.
Sharply down: the price has fallen very quickly lately (RSI 27).
The price is 47% below its 52-week high. Largest decline since 7 Jul 2026: 49% (September 2026 to November 2026).
Chart figures for advanced users
- SMA 50$6.28
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$3.75
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)27
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$3.62
- The lowest closing price of the last twelve months.
- Resistance$7.05
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Starling Oncology, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $374.94M, is number 50 of 56 companies in its industry on MEQIRI.
- MEQIRI Score 26 out of 100 (Weak): rank 711 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
None of our strength checks applies.
Weaknesses
- Loss-makingLoss of $35.54M over the last 12 months.Fundamentals 10
The score is held back by profitability and fundamentals.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the quarter to 30 Sep 2026, revenue rose 24.3% on the same quarter a year earlier.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 15%, operating −7%, net −12%. Last 12 months: net −6%.
Debt & balance sheet
Fiscal 2025Debt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- No date announced.
- Last reported
- 6 Aug 2026EPS reported −$0.08 (expected −$0.06)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.160.0%
- Revenue
- $665.01M0.0%
- Earnings per share
- −$0.030.0%
- Revenue
- $883.97M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: +27.4%Revenue and gross profit guidance raised: revenue of $650 million to $670 million, gross profit of $105 million to $110 million; adjusted EBITDA range narrowed to $2 million to $7 million.
“We now expect revenue of $650 million to $670 million, including approximately $150 million of capitation revenue, gross profit of $105 million to $110 million, adjusted EBITDA of $2 million to positive $7 million, and we still expect free cash flow in the range of positive $5 million to positive $15 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
One insider bought on the open market in the last 6 months, $254,753 in total. 2 insiders sold, $13.32M in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Chernett JoreyPurchase
9 Nov 2026, Major holder
- Shares
- 48,294
- Price
- $3.65
- Value
- $176,273
- Chernett JoreySale
6 Nov 2026, Major holder
- Shares
- 2,851,061
- Price
- $3.99
- Value
- $11.38M
- Hively BradSale
21 Aug 2026, Board
- Shares
- 298,853
- Price
- $6.51
- Value
- $1.95M
Show 1 more
- Chernett JoreyPurchase
14 Aug 2026, Major holder
- Shares
- 12,000
- Price
- $6.54
- Value
- $78,480
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Starling Oncology
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 26
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Clínica BavieraCBAV.MC $938.33M80
- TerveystaloTTALO.HE $873.42M51
- GMR SolutionsGMRS $635.3M57
- Strata Critical MedicalSRTA $536.81M47
- M1 KlinikenM12.DE $402.19M74
- AunaAUNA $347.12M43
- Viemed HealthcareVMD $345.96M65
- Community Health SystemsCYH $322.95M34
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 15 Oct 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.